Eli Lilly's new obesity treatment pill generated nearly 4,000 prescriptions during its second week following market launch, according to prescription tracking data.

The medication enters a competitive obesity drug market where pharmaceutical companies are racing to capture market share in the growing weight management sector. Novo Nordisk currently holds a significant position in this market with its existing obesity treatments.

The prescription numbers reflect early adoption patterns for the newly available treatment option. Industry analysts typically monitor initial prescription volumes to gauge market reception and potential commercial success of new pharmaceutical products.

The obesity medication market has seen increased attention from both pharmaceutical companies and investors as demand for weight management treatments continues to grow. Multiple companies are developing competing products in this therapeutic area.

Lilly's entry into the obesity treatment space represents the company's strategic expansion into metabolic health conditions, adding to its existing portfolio of diabetes and other therapeutic treatments.